📊 ANIP Key Takeaways
Is Ani Pharmaceuticals Inc. (ANIP) a Good Investment?
ANI demonstrates strong fundamental financial health with excellent liquidity (3.12x current ratio), robust free cash flow generation (52.3M with 22% margin), and healthy operating margins (16.4%). However, the 6965.8% revenue growth coupled with declining net income (-1.5%) suggests acquisition-driven growth facing integration challenges, warranting cautious optimism pending margin recovery.
ANI Pharmaceuticals shows strong fundamental momentum with very large revenue expansion, solid operating profitability, and robust free cash flow generation. The balance sheet appears healthy with good liquidity and manageable leverage, but the quality and sustainability of the extreme top-line growth need confirmation because earnings growth was much more modest than revenue growth.
Ani Pharmaceuticals Inc. Key Strengths (ANIP)
- Exceptional free cash flow generation (52.3M, 22% FCF margin) indicates quality, cash-producing business
- Excellent liquidity position (3.12x current ratio, 311.2M cash) provides strategic flexibility and financial stability
- Healthy profitability margins (16.4% operating margin, 12.4% net margin) demonstrate operational efficiency
- Conservative leverage (0.51x debt/equity, 5.1x interest coverage) and strong cash position reduce financial risk
- Positive shareholder capital allocation evidenced by EPS growth (419.2%) driven by share buybacks
- Strong free cash flow generation with $171.39M of FCF and a 19.4% FCF margin
- Healthy liquidity profile with a 2.71x current ratio, 2.19x quick ratio, and $285.58M in cash
- Profitable operations with $111.09M operating income, 12.6% operating margin, and positive ROE/ROA
ANIP Stock Risks: Ani Pharmaceuticals Inc. Investment Risks
- Extreme revenue growth (6965.8% YoY) with declining net income (-1.5%) indicates acquisition integration challenges and potential amortization burden
- Poor capital efficiency (5.2% ROE, 2.1% ROA) suggests suboptimal deployment of acquisition capital
- Missing gross margin disclosure limits visibility into cost structure and operational performance assessment
- Pharmaceutical sector faces inherent regulatory risk, patent expiration risk, and competitive pricing pressures
- High insider transaction activity (41 Form 4s in 90 days) may signal uncertainty regarding acquisition or company strategy
- Revenue growth of +6965.8% YoY may reflect acquisitions or base effects, raising questions about underlying organic growth quality
- Interest coverage of 3.4x is adequate but not especially strong for a pharmaceutical business with integration and execution risk
- Net income grew only 1.5% YoY despite massive revenue growth, suggesting possible margin pressure, acquisition costs, or earnings quality concerns
Key Metrics to Watch
- Net income and gross margin trends to confirm acquisition integration is progressing and improving operational leverage
- Return on equity (ROE) and return on assets (ROA) trajectory to validate acquisition creates shareholder value
- Free cash flow sustainability and debt-to-equity ratio to ensure financial strength is maintained through integration period
- Organic revenue growth and operating margin trend
- Interest coverage and debt reduction versus free cash flow
Ani Pharmaceuticals Inc. (ANIP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 22.0% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.12x current ratio provides a solid financial cushion.
ANIP Profit Margin, ROE & Profitability Analysis
ANIP vs Healthcare Sector: How Ani Pharmaceuticals Inc. Compares
How Ani Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ani Pharmaceuticals Inc. Stock Overvalued? ANIP Valuation Analysis 2026
Based on fundamental analysis, Ani Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ani Pharmaceuticals Inc. Balance Sheet: ANIP Debt, Cash & Liquidity
ANIP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ani Pharmaceuticals Inc.'s revenue has grown significantly by 309% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.85 reflects profitable operations.
ANIP Revenue Growth, EPS Growth & YoY Performance
ANIP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $197.1M | $15.7M | $0.69 |
| Q3 2025 | $148.3M | -$8.2M | $-0.49 |
| Q2 2025 | $138.0M | -$2.3M | $-0.14 |
| Q1 2025 | $137.4M | $15.7M | $0.69 |
| Q3 2024 | $131.8M | -$8.2M | $0.45 |
| Q2 2024 | $116.5M | -$2.3M | $-0.14 |
| Q1 2024 | $106.8M | $1.4M | $0.06 |
| Q3 2023 | $83.8M | -$8.6M | $0.45 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ani Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
ANIP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ani Pharmaceuticals Inc. (CIK: 0001023024)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANIP
What is the AI rating for ANIP?
Ani Pharmaceuticals Inc. (ANIP) has a Combined AI Grade of A from Claude (A) and ChatGPT (A) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANIP's key strengths?
Claude: Exceptional free cash flow generation (52.3M, 22% FCF margin) indicates quality, cash-producing business. Excellent liquidity position (3.12x current ratio, 311.2M cash) provides strategic flexibility and financial stability. ChatGPT: Strong free cash flow generation with $171.39M of FCF and a 19.4% FCF margin. Healthy liquidity profile with a 2.71x current ratio, 2.19x quick ratio, and $285.58M in cash.
What are the risks of investing in ANIP?
Claude: Extreme revenue growth (6965.8% YoY) with declining net income (-1.5%) indicates acquisition integration challenges and potential amortization burden. Poor capital efficiency (5.2% ROE, 2.1% ROA) suggests suboptimal deployment of acquisition capital. ChatGPT: Revenue growth of +6965.8% YoY may reflect acquisitions or base effects, raising questions about underlying organic growth quality. Interest coverage of 3.4x is adequate but not especially strong for a pharmaceutical business with integration and execution risk.
What is ANIP's revenue and growth?
Ani Pharmaceuticals Inc. reported revenue of $237.5M.
Does ANIP pay dividends?
Ani Pharmaceuticals Inc. does not currently pay dividends.
Where can I find ANIP SEC filings?
Official SEC filings for Ani Pharmaceuticals Inc. (CIK: 0001023024) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANIP's EPS?
Ani Pharmaceuticals Inc. has a diluted EPS of $1.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ANIP's fundamental grade?
Based on our AI fundamental analysis in June 2026, Ani Pharmaceuticals Inc. has a A grade with 74% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ANIP stock overvalued or undervalued?
Valuation metrics for ANIP: ROE of 5.2% (sector avg: 15%), net margin of 12.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ANIP's AI grade for 2026?
Our dual AI analysis gives Ani Pharmaceuticals Inc. a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ANIP's free cash flow?
Ani Pharmaceuticals Inc.'s operating cash flow is $58.4M, with capital expenditures of $6.1M. FCF margin is 22.0%.
How does ANIP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 12.4% (avg: 12%), ROE 5.2% (avg: 15%), current ratio 3.12 (avg: 2).